Lim Do Gyeong, Jung Seung Il, Kim Myung Soo, Chung Ho Seok, Hwang Eu Chang, Kwon Dong Deuk
Department of Urology, Chonnam National University Medical School, Gwangju, 501-757, Korea.
Prostate Int. 2021 Sep;9(3):163-168. doi: 10.1016/j.prnil.2021.03.001. Epub 2021 Apr 17.
To assess the prophylactic effect of fosfomycin (FM) and ciprofloxacin combinations for infectious complications of transrectal ultrasound-guided prostate biopsy (TRUSPB) compared to that of ciprofloxacin alone.
In total, 1,578 patients were enrolled and were divided into two groups according to the prophylactic antibiotics. Group 1 (n = 1234) received ciprofloxacin on the day of the biopsy and for an additional 1-2 days, whereas Group 2 (n = 334) was given FM in addition to ciprofloxacin in the same manner as Group 1. The primary outcome was overall infectious complications within 1 month of TRUSPB. The secondary outcome was the risk factors of infectious complications after TRUSPB.
Infectious complications occurred in 31 patients (2.5%) and 1 patient (0.3%) in Groups 1 and 2, respectively. Our results indicated that fluoroquinolone (FQ) and FM significantly reduced the risk of infectious complications compared to FQ (relative risk: 0.12; 95% confidence interval 0.02-0.87, = 0.015). Based on the multivariate analysis, previous antibiotic exposure (odds ratio [OR] = 3.59, = 0.026), and the addition of FM (OR = 0.12, = 0.038) were associated with infectious complications. Based on the rectal swab, FQ resistance was 28.0% (n = 294) in total. FQ resistance in the FQ and FM group was higher than that in the FQ group (n = 178, 54.9% vs. n = 116, 16.0%, < 0.001).
The combination of ciprofloxacin and FM exhibited reduced infectious complications after TRUSPB compared with ciprofloxacin monotherapy and may be applicable in the era of the high abundance of FQ-resistant rectal flora.
评估磷霉素(FM)与环丙沙星联合用药对比单独使用环丙沙星对经直肠超声引导下前列腺穿刺活检(TRUSPB)感染性并发症的预防效果。
共纳入1578例患者,根据预防性使用的抗生素分为两组。第1组(n = 1234)在活检当天及之后额外1 - 2天接受环丙沙星治疗,而第2组(n = 334)除与第1组同样方式使用环丙沙星外,还给予FM。主要结局是TRUSPB后1个月内的总体感染性并发症。次要结局是TRUSPB后感染性并发症的危险因素。
第1组和第2组分别有31例(2.5%)和1例(0.3%)发生感染性并发症。我们的结果表明,与单独使用氟喹诺酮(FQ)相比,FQ与FM联合显著降低了感染性并发症的风险(相对风险:0.12;95%置信区间0.02 - 0.87,P = 0.015)。基于多变量分析,既往抗生素暴露(比值比[OR] = 3.59,P = 0.026)以及添加FM(OR = 0.12,P = 0.038)与感染性并发症相关。根据直肠拭子检测,总体FQ耐药率为28.0%(n = 294)。FQ与FM联合组的FQ耐药率高于FQ组(n = 178,54.9% 对比 n = 116,16.0%,P < 0.001)。
与环丙沙星单药治疗相比,环丙沙星与FM联合用药在TRUSPB后表现出感染性并发症减少,并且可能适用于FQ耐药直肠菌群高度流行的时代。